Rare case report: a case of histological type transformation of lung cancer caused by neoadjuvant immunotherapy

Rare case report: a case of histological type transformation of lung cancer caused by neoadjuvant immunotherapy

Lung cancer remains the leading cause of cancer-related mortality, with 1.8 million deaths per year. Small cell lung cancer and non-small cell lung cancer (NSCLC) are the main cancer types. Approximately 85% of cases are NSCLC, including adenocarcinoma, squamous cell carcinoma, and large cell carcin...

Full description

Bibliographic Details
Main Authors:	Quanqing Li, Guangxin Zhang, Hao Yang, Jindong Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-02-01
Series:	Frontiers in Oncology
Subjects:	histological type transformation neoadjuvant immunotherapy small cell lung cancer drug resistance squamous cell lung carcinoma
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1329152/full

Similar Items

Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients’ overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study
by: Fuqiang Dai, et al.
Published: (2022-10-01)

Histological transformation into SCLC: An important resistance mechanism of NSCLC upon immunotherapy
by: Jiao Zeng, et al.
Published: (2023-10-01)

Lung Cancer Surgery after Neoadjuvant Immunotherapy
by: Dirk Stefani, et al.
Published: (2021-08-01)

Transformation of Lung Squamous Cell Carcinoma to Small Cell Lung Cancer After Immunotherapy Resistance: A Case Report
by: Wang D, et al.
Published: (2023-08-01)

Meta-Analysis of Neoadjuvant Immunotherapy for Patients with Resectable Non-Small Cell Lung Cancer
by: Christopher Cao, et al.
Published: (2021-11-01)

Neoadjuvant and Adjuvant Immunotherapy in Non-Small Cell Lung Cancer—Clinical Trials Experience
by: Izabela Chmielewska, et al.
Published: (2021-10-01)

Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer
by: Yunzhen Wang, et al.
Published: (2023-05-01)

Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC
by: John F. Roller, et al.
Published: (2022-01-01)

Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case Report
by: Rui-Xia Yang, et al.
Published: (2022-08-01)

Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer
by: Greta Alì, et al.
Published: (2023-02-01)

Conversion therapy with immunotherapy plus chemotherapy achieves a pathological complete response in stage IIIC NSCLC
by: Yu Fu, et al.
Published: (2023-11-01)

Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature
by: Sara Franzi, et al.
Published: (2022-05-01)

Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer
by: Jie Shen, et al.
Published: (2023-09-01)

The Efficacy and Safety of Neoadjuvant Immunotherapy in Patients with Non-Small Cell Lung Cancer
by: Deniz Can Guven, et al.
Published: (2023-12-01)

Plasma extracellular vesicle long RNAs predict response to neoadjuvant immunotherapy and survival in patients with non‐small cell lung cancer
by: Wei Guo, et al.
Published: (2023-10-01)

Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future
by: Chun Ho Szeto, et al.
Published: (2021-11-01)

Will neo-adjuvant immunotherapy become a new paradigm in the treatment of lung cancer patients
by: K. K. Laktionov, et al.
Published: (2019-12-01)

Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer
by: Chang QI, et al.
Published: (2024-02-01)

Evaluation of the efficacy and surgical-related safety of neoadjuvant immunochemotherapy in advanced resectable none small cell lung cancer (NSCLC)
by: Qin Wang, et al.
Published: (2023-12-01)

The earlier, the better? A review of neoadjuvant immunotherapy in resectable non‐small‐cell lung cancer
by: Fajiu Li, et al.
Published: (2022-06-01)

Immunotherapy for small-cell lung cancer
by: A. Ye. Kuzminov, et al.
Published: (2019-06-01)

Efficacy of neoadjuvant immunochemotherapy and survival surrogate analysis of neoadjuvant treatment in IB–IIIB lung squamous cell carcinoma
by: Jiacong Liu, et al.
Published: (2024-03-01)

Is response evaluation criteria in solid tumors (RECIST) effective in patient selection for radical resection after neoadjuvant immunotherapy with advanced NSCLC?
by: Yuan Xu, et al.
Published: (2023-06-01)

Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma
by: Xu H, et al.
Published: (2022-12-01)

Neoadjuvant Radiotherapy/Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer
by: Deniz Yalman
Published: (2015-03-01)

Editorial: Impact of immunotherapy in lung cancer
by: Marion Ferreira, et al.
Published: (2022-11-01)

Perioperative immunotherapy for stage II-III non-small cell lung cancer: a meta-analysis base on randomized controlled trials
by: Anping Yu, et al.
Published: (2024-02-01)

Comparison of neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable stage III non-small cell lung cancer: a real-world cohort study
by: Sihao Zhou, et al.
Published: (2023-12-01)

Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer
by: Ye Tao, et al.
Published: (2023-05-01)

Study on the efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy regimen for III–IVA esophageal squamous cell carcinoma post-surgery
by: Chunyang Li, et al.
Published: (2024-01-01)

Pathological complete response to neoadjuvant therapy with serplulimab and chemotherapy in stage IIIB small cell lung cancer: a case report and literature review
by: Ting Mei, et al.
Published: (2024-01-01)

Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Chemotherapy versus Chemotherapy Alone in Non-Small Cell Lung Cancer: A Propensity Score and Inverse Probability Treatment Weighting Analysis
by: Zhao J, et al.
Published: (2023-11-01)

Lung adenocarcinoma relapse with emerging EGFR mutation following complete response of small cell lung cancer warrants routine re-biopsy: A case report
by: Minna Zhang, et al.
Published: (2022-10-01)

Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
by: Xin Li, et al.
Published: (2022-09-01)

The advances in immunotherapy biomarkers of small cell lung cancer
by: XIE Mengqing, CHU Xiangling, ZHOU Juan, SU Chunxia
Published: (2021-07-01)

Neoadjuvant immunotherapy for resectable esophagal squamous cell carcinoma: An ace up the sleeve
by: Qing Zhou, et al.
Published: (2023-09-01)

Clinical Progress in the Immunotherapy of Small Cell Lung Cancer
by: Weiwei WANG, et al.
Published: (2022-06-01)

Neoadjuvant immunochemotherapy with pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
by: Yulong Chen, et al.
Published: (2023-09-01)

Clinical factors and major pathological response after neoadjuvant chemoimmunotherapy in potentially resectable lung squamous cell carcinoma
by: Ye Wang, et al.
Published: (2024-04-01)

Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy
by: Apar Pataer, MD, PhD, et al.
Published: (2022-11-01)